{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:13:12Z","timestamp":1780549992624,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009093","name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.medcli.2021.03.041","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T04:35:56Z","timestamp":1624941356000},"page":"440-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Actualizaci\u00f3n en el diagn\u00f3stico, pron\u00f3stico y tratamiento del linfoma folicular"],"prefix":"10.1016","volume":"157","author":[{"given":"Pablo","family":"Mozas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Sorigu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2021.03.041_bib0305","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00277-020-03918-6","article-title":"RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group","volume":"99","author":"Bastos-Oreiro","year":"2020","journal-title":"Ann Hematol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0310","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(15)00155-6","article-title":"Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: Comparison between European population-based data (EUROCARE-5)","author":"Mounier","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0315","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.52.8190","article-title":"t(14;18) translocation: A predictive blood biomarker for follicular lymphoma","author":"Roulland","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0320","doi-asserted-by":"crossref","DOI":"10.1093\/jncimonographs\/lgu013","article-title":"Etiologic heterogeneity among non-hodgkin lymphoma subtypes: The interLymph non-hodgkin lymphoma subtypes project","author":"Morton","year":"2014","journal-title":"J Natl Cancer Inst - Monogr."},{"key":"10.1016\/j.medcli.2021.03.041_bib0325","doi-asserted-by":"crossref","DOI":"10.1038\/nri3814","article-title":"Germinal centres and B cell lymphomagenesis","author":"Basso","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0330","doi-asserted-by":"crossref","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","author":"Tsujimoto","year":"1985","journal-title":"Science (80-)."},{"key":"10.1016\/j.medcli.2021.03.041_bib0335","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2021.03.041_bib0340","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.beha.2011.02.007","article-title":"The microenvironment in follicular lymphoma","volume":"24","author":"De Jong","year":"2011","journal-title":"Best Pract Res Clin Haematol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0345","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon","author":"Swerdlow","year":"2017","journal-title":"France."},{"key":"10.1016\/j.medcli.2021.03.041_bib0350","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.medcli.2021.03.041_bib0355","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Dreyling","year":"2020","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0360","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-0299-0","article-title":"Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience","volume":"10","author":"Mozas","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.medcli.2021.03.041_bib0370","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: Long-term results of the PRIMA Study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0375","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: A pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0380","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0385","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0390","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2021.03.041_bib0395","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2006-01-013367","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vinc","author":"Buske","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2021.03.041_bib0400","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0405","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2021.03.041_bib0410","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: A retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0415","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0420","article-title":"Genomic alterations important for the prognosis in patients with follicular lymphoma treated on SWOG study S0016","author":"Qu","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2021.03.041_bib0425","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0430","first-page":"1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"2045","author":"Trotman","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0435","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115930","article-title":"Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients","author":"Pott","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2021.03.041_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428194.2011.629897","article-title":"Clinical practice guidelines for first-line\/after-relapse treatment of patients with follicular lymphoma","volume":"52","author":"L\u00f3pez-Guillermo","year":"2011","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2021.03.041_bib0445","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0450","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0455","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular Lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0460","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0465","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0470","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","article-title":"Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma","volume":"98","author":"Bachy","year":"2013","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2021.03.041_bib0475","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2021.03.041_bib0480","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0485","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00262","article-title":"Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up","author":"Lockmer","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0490","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0495","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/hon.2378","article-title":"Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome","volume":"35","author":"Sorigue","year":"2017","journal-title":"Hematol Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0500","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma Subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0505","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/1078155215603230","article-title":"Randomized controlled trials in relapsed\/refractory follicular lymphoma: A systematic review and meta-analysis","volume":"22","author":"Police","year":"2016","journal-title":"J Oncol Pharm Pract."},{"key":"10.1016\/j.medcli.2021.03.041_bib0510","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bjh.15708","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0515","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study","volume":"184","author":"Link","year":"2019","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0520","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2021.03.041_bib0525","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3324\/haematol.2012.069583","article-title":"Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2021.03.041_bib0530","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","article-title":"Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2021.03.041_bib0535","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2021.03.041_bib0540","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","article-title":"Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study","volume":"96","author":"Le Gouill","year":"2011","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2021.03.041_bib0545","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41409-018-0372-5","article-title":"The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies","author":"Norman","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.medcli.2021.03.041_bib0550","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.31264","article-title":"Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR","volume":"124","author":"Sureda","year":"2018","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2021.03.041_bib0555","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.beha.2017.11.003","article-title":"Novel agents for relapsed and refractory follicular lymphoma","volume":"31","author":"Cheah","year":"2018","journal-title":"Best Pract Res Clin Haematol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0560","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2021.03.041_bib0565","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/14737140.2017.1285702","article-title":"Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow","volume":"17","author":"Greenwell","year":"2017","journal-title":"Expert Rev Anticancer Ther."},{"key":"10.1016\/j.medcli.2021.03.041_bib0570","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0575","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2021.03.041_bib0580","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/annonc\/mdx407","article-title":"Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma","volume":"28","author":"Magnano","year":"2017","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0585","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0590","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2021.03.041_bib0595","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.hoc.2020.03.001","article-title":"Treatment of Histologic Transformation","volume":"34","author":"Casulo","year":"2020","journal-title":"Hematol Oncol Clin North Am."},{"key":"10.1016\/j.medcli.2021.03.041_bib0600","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/cncr.31821","article-title":"Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes","volume":"125","author":"Hester","year":"2019","journal-title":"Cancer."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002577532100333X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002577532100333X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:53:34Z","timestamp":1758419614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002577532100333X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S002577532100333X"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2021.03.041","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualizaci\u00f3n en el diagn\u00f3stico, pron\u00f3stico y tratamiento del linfoma folicular","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2021.03.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}